Company Overview

BMR has extensive experience and technical expertise in the field of therapeutic antibodies in particular and through these, we have so far developed antibodies for respiratory infections such as influenza viruses.

BMR supplies highly sensitive antibodies to manufacturers of rapid diagnostic test kits, and has already occupied more than 50% market share in this segment to date.

The market for diagnostic kits for respiratory infections is concentrated in industrialized nations in the Northern Hemisphere. A major disruptor in this market is the incidence of tropical infections such as mosquito-borne malaria. Malaria tests, for example, are performed more than eight times as often as influenza tests.

With the addition of malaria and dengue fever antibody diagnostic materials to our product range, BMR has made a significant contribution to this highly specialized yet very important field of health care.

Company Name
Bio Matrix Research, Inc.
Date founded
March 28, 2002
Capital
95,500,000 yen (as of December 31, 2016)
Representative
Shunsuke Matsunaga, President
Main activities
Developing and distributing monoclonal antibody materials for rapid diagnostic kits

Corporate History

March 2002
Bio Matrix Research founded in Noda-shi, Chiba
Initial operations include development of transcription factor antibody and genetic analyses (microassay sequencing) on consignment
August 2003
Head office and sales department relocates to Kashiwa-shi, Chiba
New laboratory opens at Tokatsu Techno Plaza in Kashiwa-shi, Chiba
January 2004
New sales office opens in Nishi-ku, Osaka-shi
November 2004
New laboratory opens at Todai-Kashiwa Venture Plaza, Kashiwa-shi, Chiba prefecture
March 2006
Head office relocates to Nagareyama-shi, Chiba
December 2007
Start developing antibody materials for influenza rapid diagnostic kits
June 2009
Start developing antibody drugs
August 2010
First antibody materials for influenza rapid diagnostic kits released onto the market
March 2012
Overhaul of management structure positions antibodies as the primary focus of development, manufacturing and distribution resources
April 2015
Operations are consolidated at Nagareyama head office
March 2016
Start developing antibody materials for tropical infectious diseases